Illumina Announces Phasing Analysis Service for Human Whole-Genome Sequencing Human Whole-Genome Phasing Solution Expands Insight into Complex Genomes SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc ...

Illumina said adding SomaLogic would support the company’s multiomics strategy and strengthen the value of its NovaSeq X ...

Illumina’s new sequencing series includes a pair of new instruments—the NovaSeq X and NovaSeq X Plus. ... Johnson tells GEN that the company redesigned the blocker to reduce phasing.

Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains ...

Illumina has captured more than 70% of the sequencing market with these machines that it sells to academics, pharmaceutical companies, biotech companies, and more.

Illumina is diving deeper into proteomics research with a $425 million plan to acquire SomaLogic, including its protein ...

San Diego gene sequencing giant Illumina is investing more in artificial intelligence to fuel the company’s growth strategy ...

Illumina Inc., a global leader in DNA sequencing and array-based technologies, today announced that its first product based on its novel Illumina Complete Long Read technology is now available to ...

The deal is intended to strengthen Illumina’s in-house capabilities to expand genomic technology into clinical settings and prepare for its next growth phase, the sequencing giant said.